← Back to Search

Stem Cell Transplantation

Stem Cell Transplantation for Multiple Myeloma

N/A
Waitlist Available
Led By Denise Correa, PhD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosed with multiple myeloma and in complete, partial or very good partial remission at enrollment as per standard International Myeloma Working Group Criteria
Age 60 - 75 years at study entry
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 months following chemotherapy and asct
Awards & highlights

Study Summary

This trial will test if high-dose chemotherapy followed by ASCT affects thinking skills and brain anatomy/function in adults with multiple myeloma.

Who is the study for?
This trial is for adults aged 60-75 with multiple myeloma in remission, scheduled for high-dose chemotherapy and stem cell transplantation. Participants must speak English 'very well' and not have a history of certain cancers, neurological disorders, major psychiatric conditions, substance abuse, or recent changes to depression/anxiety medication doses.Check my eligibility
What is being tested?
The study examines cognitive abilities and brain changes in older patients receiving high-dose chemotherapy followed by autologous stem cell transplantation (ASCT). It involves various tests like memory skills assessments and brain imaging to understand the treatment's impact on neurocognitive functions.See study design
What are the potential side effects?
While specific side effects are not listed for the cognitive tests and imaging procedures used in this trial, typical risks may include discomfort during blood draws or potential anxiety from MRI scans due to claustrophobia or loud noises.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My multiple myeloma is in remission.
Select...
I am between 60 and 75 years old.
Select...
I am scheduled for high-dose chemotherapy and a stem cell transplant.
Select...
I can speak and understand English well enough for study requirements.
Select...
I speak English very well, even though it's not my first language.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 months following chemotherapy and asct
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 months following chemotherapy and asct for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Changes in neurocognitive functions in older participants with Multiple Myeloma following high-dose (HD) chemotherapy and autologous stem cell transplantation (ASCT) assessed by initial and follow-up neurocognitive evaluation
Changes in regional brain volume and functional connectivity when baseline and follow-up MRIs are compared.

Trial Design

1Treatment groups
Experimental Treatment
Group I: rsfMRI + Neurocognitive TestsExperimental Treatment11 Interventions
Participants diagnosed with multiple myeloma in complete, partial or very good partial remission per standard International Myeloma Working Group Criteria will complete neurocognitive tests and structural and functional rsfMRI (brain MRIs).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Trail Making Test (Parts A & B)
2018
N/A
~20
The Center for Epidemiological Study-Depression
2018
N/A
~20
Hopkins Verbal Learning Test-Revised
2018
N/A
~20
Auditory Consonant Trigrams Test
2018
N/A
~20
Brief Test of Attention
2016
N/A
~40
Structural Image
2018
N/A
~20
The Functional Assessment of Chronic Illness Therapy-Fatigue Subscale, Version 4
2018
N/A
~20
Controlled Oral Word Association Test
2018
N/A
~20
Functional Image
2018
N/A
~20
Digit Span subtest
2018
N/A
~20

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,928 Previous Clinical Trials
591,790 Total Patients Enrolled
80 Trials studying Multiple Myeloma
86,149 Patients Enrolled for Multiple Myeloma
Denise Correa, PhDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
4 Previous Clinical Trials
177 Total Patients Enrolled

Media Library

Autologous Stem Cell Transplantation (Stem Cell Transplantation) Clinical Trial Eligibility Overview. Trial Name: NCT03508765 — N/A
Multiple Myeloma Research Study Groups: rsfMRI + Neurocognitive Tests
Multiple Myeloma Clinical Trial 2023: Autologous Stem Cell Transplantation Highlights & Side Effects. Trial Name: NCT03508765 — N/A
Autologous Stem Cell Transplantation (Stem Cell Transplantation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03508765 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the eligibility criteria of this study limited to participants under 55 years old?

"Qualified applicants for this medical experiment must be between 60 and 75 years of age. Other trials exist that involve individuals under 18 (39) or 65 plus (794)."

Answered by AI

Are additional participants being taken into consideration for this experiment?

"Information on clinicaltrials.gov reveals that this medical study is not presently enrolling participants. Initially posted on March 27th 2018, the trial was last modified on March 9th 2022. Despite its inactivity as of now, there are 808 other trials currently seeking patients for their research."

Answered by AI

What qualifications do prospective participants need to fulfill in order to join this investigation?

"This research is searching for 18 individuals diagnosed with multiple myeloma between the ages of 60 and 75. This study requires that applicants are able to communicate effectively in English, have been evaluated according to International Myeloma Working Group Criteria and be scheduled for high-dose chemotherapy and ASCT treatments. Those whose native tongue is not English must demonstrate they possess a proficient level of comprehension by answering "very well" when prompted with the US Census' question on language fluency."

Answered by AI
~3 spots leftby Mar 2025